Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus velezensis YHX003J
- Development stage
- Preclinical
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical, Inhalation
01
Overview
*Bacillus velezensis* YHX003J is a specialized strain of Gram-positive, endospore-forming bacteria developed as a live biotherapeutic product (LBP) for the management of cat hair allergies. It is utilized as a key active component in an environmental probiotic spray intervention designed to alleviate symptoms in patients with cat allergy-induced allergic rhinitis and allergic asthma. The primary mechanism of action involves the secretion of extracellular proteases, including subtilisin-type enzymes, which enzymatically degrade the major cat dander allergen, Fel d 1, in the patient's immediate surroundings (such as bedding, carpets, and air). By lowering the concentration of environmental allergens, the strain reduces the immunological triggers that drive airway inflammation and allergic symptoms. This strain is currently being evaluated in clinical trials as part of a multi-strain probiotic formulation sponsored by the Second Affiliated Hospital of Zhejiang University School of Medicine.
- Other names
- Bacillus velezensis strain YHX003J
Beyond the preview
Go deeper on Bacillus velezensis YHX003J.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacillus velezensis YHX003J.